Testosterone buciclate is a long-acting androgen ester. Testosterone buciclate is a promising agent for the research of male hypogonadism[1][2].
Testosterone buciclate (i.m. at four sites, 20 mg/site, on days 1 and 91 of the study period, 360 days) shows reduced testicular volume (days 90-270), suppresses sperm motility and gel penetrability (days 45-240 except on day 120), decreases sperm count (days 75-270), and an increased percentage of spermatozoa showing retention of cytoplasmic droplet and coiled tail (days 45-240 except on day 120)[1].
[1]. TschÖp M, et al. A time-resolved fluorescence immunoassay for the measurement of testosterone in saliva: monitoring of testosterone replacement therapy with testosterone buciclate. Clin Chem Lab Med. 1998;36(4):223-230. [2]. Kinger S, et al. Effects of testosterone buciclate on testicular and epididymal sperm functions in bonnet monkeys (Macaca radiata) [published correction appears in Contraception 1995 Nov;52(5):323]. Contraception. 1995;52(2):121-127.